

# Scientific Program

Sunday 28 October 2018

07:30-17:00	<b>Registration desk open</b>	
08:30-08:45	<b>Conference opening</b>	
	<b>Welcome Ceremony</b> Siyan Zhan, Peking University, China Alison Bourke, FISPE, President, International Society for Pharmacoepidemiology; IQVIA, UK	
08:45-09:45	<b>Plenary address</b>	
	<b>Chairs:</b> Jesper Hallas, FISPE, University of Southern Denmark, Denmark and Huan Yang, Senior reviewer of the Clinical Division of Biological Products, Centre for Drug Evaluation, China	
	<b>Evidence for decision making throughout the product life-span - 100</b> Stella Blackburn, FISPE, VP, Global Head of Early Access and Risk Management, Real World Evidence Solutions, IQVIA, UK	
09:45-10:10	<b>Morning tea and poster viewing</b>	
10:15-11:45	<b>Symposium 1: Real World Evidence or clinical trials? Which should I believe?</b>	<b>Oral presentation session 1: Issues of safety</b>
	<b>Moderated by:</b> Stella Blackburn, FISPE, IQVIA, UK	<b>Moderated by:</b> Mary Ritchey, RTI Health Solutions, USA and Shusen Liu, MSD Pharmacoepidemiology AP Unit, China
10:15-10:30	<b>Introduction and overview</b> Stella Blackburn, FISPE, IQVIA, UK	<b>Drug safety signal detection in regional healthcare database using the tree-based scan statistic and comparison to 3 other statistical methods - 101</b> Hailong Li, Peking University Health Science Center; West China Second University Hospital, China Siyan Zhan, Peking University Health Science Center, China
10:30-10:45	<b>The Use of RWE to Augment or Replace RCTs: A Perspective on Current Research</b> Jeremy Rassen, Aetion Inc, USA	<b>Adverse reaction signal detection for statins in regional healthcare database using tree-based scan statistic method - 102</b> Hailong Li, Peking University Health Science Center, China; West China Second University Hospital, China Siyan Zhan, Peking University Health Science Center, China
10:45-11:00	<b>The practical problems of deciding on recommendations for drug use when there is mainly CT data and we know the RW experience will be different</b> Debra Rowett, The University of South Australia, Australia	<b>Novel HLA genotype subclass clustering methods to characterize liver toxicity phenotype - 103</b> Shankai Yan, City University of Hong Kong, Hong Kong
11:00-11:15	<b>The Salford Lung Study – how a study with an investigational drug was carried out in a usual care setting</b> Andrew Roddam, GlaxoSmithKline, UK	<b>Multiple imputation and clinico-serological models to predict human papilloma virus (HPV) status in oropharyngeal carcinoma: an alternative when tissue is unavailable - 104</b> Jianjun Ren, Princess Margaret Cancer Center, Canada; West China Hospital, Sichuan University, China
11:15-11:30	<b>Panel discussion</b>	<b>Impact of administration schedules on high-dose methotrexate medication in osteosarcoma: a systematic review and meta-analysis - 105</b> Zhen-Cheng Huang, Peking University, China
11:30-11:45		<b>Post-marketing safety surveillance and evaluation of moxifloxacin based on a computer-assisted adverse drug reaction alarm and assessment system - 106</b> Wangping Jia, The General Hospital of People's Liberation Army (301 Hospital), China
11:45-12:40	<b>Lunch and poster presentations</b> A. Pharmacoepidemiology and Pharmacovigilance research methods C. Drug safety risk monitoring, evaluation and prevention E. Evidence-based medicine G. Drug utilization evaluation studies I. Pharmacoepidemiology and traditional medicines	
12:45-13:25	<b>Plenary address</b>	
	<b>Chairs:</b> Wei Zhou, FISPE, MSD Research Laboratories, USA and Hua-wen Xin, Wuhan General Hospital of PLA, China	
	<b>Pharmacoepidemiology of prokinetic agents - 107</b> Kaichun Wu, Chief Professor, Department of Gastroenterology, Xijing Hospital, Fourth Military Medical University, Xi'an, China	



13:30-15:00	<b>Symposium 2: The new advancements, strength and limitations on observational drug effect studies based on large healthcare databases</b> <b>Moderated by:</b> Hongbo Yuan, Canadian Agency for Drugs and Technologies in Health, Canada	<b>Oral presentation session 2: Childhood issues</b> <b>Moderated by:</b> Vincent Lo Re, FISPE, University of Pennsylvania, USA and Yanyan Jia, Xijing Hospital, China
13:30-13:45	<b>Data sources and quality considerations in Pharmacoepidemiology and outcome research</b> Xuerong Wen, University of Rhode Island; University of Florida, USA	<b>Birth cohort effect of varicella infection before and after introducing varicella vaccination, South Korea, 2002-2017 - 108</b> Young-Jin Ko, Seoul National University College of Medicine, South Korea
13:45-14:00	<b>Is machine learning the future of Pharmacoepidemiology?</b> Robert Platt, McGill University, Canada	<b>Incidence rates of health outcomes of interest among Chinese children exposed to selected vaccines: a population based retrospective cohort study - 109</b> Kui Huang, Pfizer Inc, USA
14:00-14:15	<b>'Real World Evidence' in health care decision-making</b> Hongbo Yuan, Canadian Agency for Drugs and Technologies in Health, Canada	<b>Prescription patterns of antidiabetic medications during pregnancy in South Korea, 2006-2013 - 110</b> Yunha Noh, Sungkyunkwan University, South Korea
14:15-14:30	<b>Validation of safety signals: the good and the bad</b> Abraham G Hartzema, FISPE, University of Florida, USA	<b>Developmental outcomes at age four following maternal antiepileptic use - 111</b> Noni Richards, University of Otago, New Zealand
14:30-14:45	<b>The practice in the Asia-Pacific region: evidence generation and application</b> Nicole Pratt, The University of South Australia, Australia	<b>Infant antibiotic use increases the risk of childhood asthma - 112</b> Pingsheng Wu, Vanderbilt University Medical Center, USA
14:45-15:00	Panel discussion	<b>Comparative effect of four antimalarial treatments on haematocrit in children in Southwest of Nigeria - 113</b> Zachaeus Olofin, University of Ibadan, Nigeria
15:00-15:25	<b>Afternoon tea and poster viewing</b>	
15:30-17:00	<b>Symposium 3: Heterogeneity and validity in national and international Multi-Databases Pharmacoepidemiologic Studies (MPES): lessons learned in North America, Europe and Asia</b> <b>Moderated by:</b> Soko Setoguchi, FISPE, Rutgers University, USA and Jesper Hallas, FISPE, University of Southern Denmark, Denmark	<b>Oral presentation session 3: Cardiovascular issues</b> <b>Moderated by:</b> Byung Joo Park, FISPE, Seoul National University, Korea and Qiang Li, Boehringer Ingelheim Investment Co Ltd, China
15:30-15:45	<b>How to deal with variations across sites for a valid MPES. Experience and perspective as coordinating center for the US FDA sentinel initiative studies</b> Darren Toh, FISPE, Harvard University, The USA	<b>Thromboembolism, bleeding, and mortality among patients with atrial fibrillation treated with dual antiplatelet therapy versus oral anticoagulants: a population-based study - 114</b> Wallis Lau, UCL School of Pharmacy, UK; University of Hong Kong, Hong Kong
15:45-16:00	<b>When it is appropriate to aggregate the results from multiple databases? Experience in the Canadian Network for Observational Drug Effect Studies (CNODES)</b> Robert Platt, McGill University, Canada	<b>Implementation of a novel design in evaluating oral anti-coagulant effectiveness and safety: a prevalent new user design study - 115</b> Hui-Min Lin, National Taiwan University; National Taiwan University Hospital, Taiwan
16:00-16:15	<b>How to interpret the results of MPSE appropriately. Experience in the multi-continent MPES.</b> Kenneth Man, UCL School of Pharmacy, UK	<b>Prevalence, safety and effectiveness of oral anticoagulant use in people with and without dementia: a systematic review and meta-analysis - 116</b> Laura Fanning, Monash University, Australia
16:15-16:30	<b>Measured and unmeasured heterogeneity specifically for Asian countries MPES. The experiences from Asian Pharmacoepidemiology Network (ASPEN) and future developments</b> Edward Chia Cheng Lai, National Cheng Kung University, Taiwan	<b>Renal function change during bisphosphonate use in patients with chronic kidney disease - 117</b> Victoria Y Strauss, University of Oxford, UK
16:30-16:45	Panel discussion	<b>Trends and predictors of oral anticoagulant use in people with dementia and the general population of older adults in Australia - 118</b> Jenni Ilomaki, Monash University, Australia
16:45-17:00		<b>Use of falls risk medications in people at high and low falls risk in aged care services - 119</b> Kate Wang, Monash University, Australia
17:00	End of day	
19:00-22:00	<b>Conference dinner</b> Shaanxi, 75 Chang'an North Road, Xi'an Buses will depart the Wyndham Grand Xi'an South Hotel from 18:15	

07:30-17:00	<b>Registration desk open</b>	
08:30-10:00	<b>Multi-national Pharmacoepidemiology study in the Asia-Pacific region: the application of distributed network approach in the AsPEN</b>	
	<b>Moderated by:</b> Soko Setoguchi, FISPE, Rutgers Robert Wood Johnson Medical School, USA and Edward Lai, National Cheng Kung University, Taiwan	
	Nicole Pratt, University of South Australia, Australia Kenneth Man, UCL School of Pharmacy, UK Kui Huang, Pfizer Ltd, USA Edward Lai, National Cheng Kung University, Taiwan Nam-Kyong Choi, EWHA Women's University, Korea	
10:00-10:25	<b>Morning tea and poster viewing</b>	
10:30-12:00	<b>Oral presentation session 4: Medicine use issues</b>	<b>Oral presentation session 5: Potpourri</b>
	<b>Moderated by:</b> Sallie Pearson, University of New South Wales, Australia and Hong Cheng, Zhongnan Hospital, Wuhan University, China	<b>Moderated by:</b> K. Arnold Chan, FISPE, National Taiwan University, Taiwan and Feng Sun, Peking University, China
10:30-10:45	<b>Knowledge, attitudes and practices towards generic substitution: a cross-sectional study among endocrinologists in China - 120</b> Mingyue Zhao, Jiaotong University; Shaanxi Center for Health Reform and Development Research, China	<b>VALIDATE-J: a validation study of rheumatoid arthritis in Japanese claims data - 126</b> Soko Setoguchi, FISPE, Rutgers Robert Wood Johnson Medical School, USA
10:45-11:00	<b>Treatment initiation for type 2 diabetes in Australia: are the guidelines being followed? - 121</b> Stephen Wood, Monash University, Australia	<b>Diagnosis- and external cause-based criteria to identify adverse drug reactions in hospital ICD-coded data - 127</b> Wei Du, The Australian National University, Australia
11:00-11:15	<b>Impact of a clinical pharmacist-led post-hospitalization care on clinical and humanistic outcomes among acute coronary syndrome patients: randomized controlled study - 122</b> Krishna Undela, JSS College of Pharmacy, JSS Academy of Higher Education & Research, India	<b>Accuracy of molecular diagnostic tests for the detection of drug-resistant tuberculosis in China: a systematic review and meta-analysis - 128</b> Yixin Sun, Peking University, China
11:15-11:30	<b>Polypharmacy and risk factors in patients with myocardial infarction or stroke - 123</b> Tian-Tian Ma, UCL School of Pharmacy, UK	<b>Dipeptidyl peptidase-4 inhibitors and risk of inflammatory bowel disease among patients with T2D: a meta-analysis of randomized controlled trials - 129</b> Guangyao Li, Beijing Shijitan Hospital, Capital Medical University; Peking University, China
11:30-11:45	<b>Trends in hospitalised adverse drug events in New South Wales, Australia - 124</b> Hanwen Zhang, The Australian National University, Australia	<b>Prescribing trend of pioglitazone after safety warning release in South Korea: a population-based interrupted time series study - 130</b> Han Eol Jeong, Sungkyunkwan University, South Korea
11:45-12:00	<b>Characteristics of post-marketing observational studies in China: 2013-2018 - 125</b> Yinghui Liu, Real-World Evidence Solutions, IQVIA, China	<b>Impact of incretin-based therapies on neurological manifestation among type 2 diabetes: a systematic review and network meta-analysis - 131</b> Le Gao, Peking University, China
12:00-13:10	<b>Lunch and poster presentations</b> B. Post-marketing drug effectiveness and safety evaluation D. Pharmacogenomics research and drug safety F. Evidence-based pharmacy H. Rational drug use	

13:15-14:45	<b>Symposium 4: Opportunities of Pharmacoepidemiologists in precision medicine in China</b> <b>Moderated by:</b> Andrew Roddam, GlaxoSmithKline, UK	<b>Oral presentation session 6: Issues of the mind</b> <b>Moderated by:</b> Alison Bourke, FISPE, IQVIA, UK and Jian Gong, Shenyang Pharmaceutical University, China
13:15-13:30	<b>Precision oncology for Pharmacoepidemiologists: study design and implementation strategies</b> Geoffrey Liu, FISPE, University of Toronto; Princess Margaret Cancer Centre, Canada	<b>Partner bereavement and risk of psoriasis: population-based cohort study in the UK - 132</b> Angel Wong, London School of Hygiene and Tropical Medicine, UK
13:30-13:45	<b>The precision medicine initiative in China: new opportunities for pharmacogenomics</b> Meng Zhu, Nanjing Medical University, China	<b>Combined use of antidepressants or non-steroidal anti-inflammatory drugs and the risk of intracranial haemorrhage: a nationwide cohort study - 133</b> Han Eol Jeong, Sungkyunkwan University, South Korea
13:45-14:00	<b>Genetic variation of adverse effects associated with first-line treatment of tuberculosis</b> Siyan Zhan, Peking University, China	<b>Modelling the risks and benefits of antipsychotics in schizophrenia: application of a novel regression-based risk-benefit approach - 134</b> Te-yuan Chyou, University of Otago, New Zealand
14:00-14:15	<b>Statistical methodology for Pharmacoepidemiology: modeling and analysis</b> Wei Xu, University of Toronto, Canada	<b>Incidence of all-cause, sudden death, and cardiovascular mortality among antipsychotic-treated patients with schizophrenia in Taiwan - 135</b> Darmendra Ramcharran, Janssen Research & Development (J&J), USA
14:15-14:30	Panel discussion	<b>Analysis of group-based trajectory model for sustained use of opioid analgesics in South Korea - 136</b> Dongwon Yoon, Sungkyunkwan University, South Korea
14:30-14:45		<b>Pharmaceutical opioid use and mortalities among older Australians - 137</b> Wei Du, The Australian National University, Australia
<b>14:45-15:10</b>	<b>Afternoon tea and poster viewing</b>	
15:15-16:40	<b>Symposium 5: Real World Data and Real World Evidence for evaluating drug safety and effectiveness: evolution, development, and perspective in China, Japan and USA</b> <b>Moderated by:</b> Siyan Zhan, Peking University, China and Xiaofeng Zhou, Pfizer, USA	
	<b>The development of ADR monitoring in China</b> Haibo Song, Center of Drug Reevaluation, CFDA, China	
	<b>Utilization of real-world data for Pharmacovigilance activities in Japan</b> Kazuhiro Kajiyama, Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency (PMDA), Japan	
	<b>Sentinel and PCORnet</b> Darren Toh, FISPE, Harvard Medical School and Harvard Pilgrim Health Care Institute, USA	
	<b>An introduction to the reform of Drug Evaluation System in China</b> Baoshu Wen, Center of Drug Evaluation, CFDA, China	
16:40-17:00	<b>Closing and award ceremony</b>	

